淋巴水肿的发病机制及治疗进展研究-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

淋巴水肿的发病机制及治疗进展研究

Research on the Pathogenesis and Treatment Progress of Lymphedema

ES评分 0 浏览量：45 下载量：0

DOI	10.12208/j.ijcr.20250278
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2025, 9(6)
作者	冯亮¹,夏华²,吴卫红²,饶弋²,朱思³,谭岁赛²*,
作者单位	1 吉首大学湖南吉首,2 益阳市中心医院血管外科湖南益阳,3 市中心医院内科湖南益阳
摘要	淋巴水肿是一种因淋巴液回流障碍导致的慢性疾病，发病率呈上升趋势。本文综述其发病机制与治疗进展：原发性淋巴水肿与 VEGFR-3等基因异常有关，继发性淋巴水肿多由手术、放疗、感染等因素引发。治疗方面，保守治疗以综合消肿疗法为主，结合物理技术与新型药物；外科治疗通过 LVA、VLNT等手术重建淋巴通路，干细胞技术展现应用潜力。目前存在早期诊断困难、个体化方案不足等问题，未来需在靶向药物、人工智能诊断等方向深入研究，以推动淋巴水肿诊疗的精准化与高效化。
Abstract	Lymphedema is a chronic disease caused by the disorder of lymphatic fluid reflux, and its incidence rate is on the rise. This article reviews its pathogenesis and treatment progress: Primary lymphedema is related to gene abnormalities such as VEGFR-3, while secondary lymphedema is mostly caused by factors such as surgery, radiotherapy, and infection. In terms of treatment, conservative treatment mainly focuses on comprehensive swelling reduction therapy, combined with physical techniques and new drugs. Surgical treatment reconstructs lymphatic pathways through surgeries such as LVA and VLNT, and stem cell technology shows its application potential. At present, there are problems such as difficulties in early diagnosis and insufficient individualized plans. In the future, in-depth research is needed in directions such as targeted drugs and artificial intelligence diagnosis to promote the precision and efficiency of lymphedema diagnosis and treatment.
关键词	淋巴水肿；发病机制；综合消肿疗法；超显微外科；
KeyWord	Lymphedema;Pathogenesis; Comprehensive anti-swelling therapy ;Ultra-microsurgery
基金项目
页码	38-43

参考文献
相关文献

[1] 中华整形外科学分会淋巴水肿组 .外周淋巴水肿诊疗的中国专家共识
[J].中华整形外科杂志,2020,36(4):355-360.
[2] Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
[J].CA Cancer J Clin,2021,71(3):209-249.
[3] Siegel RL,Miller KD,Wagle NS,et al.Cancer statistics,2023
[J]. CA Cancer J Clin,2023,73(1):17-48.
[4] CARLSON J W, KAUDERER J, HUTSON A, et al. GOG 244-The lymphedema and gynecologic cancer (LEG) study: incidence and risk factors in newly diagnosed patients［J］. Gynecol Oncol, 2020, 156(2): 467-474.
[5] 孙沣,张涤生.原发性肢体淋巴水肿发病机制研究进展［J］.国外医学外科学分册, 2003, 30(2): 1.
[6] 刘宁飞. 外周淋巴水肿的治疗［J］.中华整形外科杂志, 2018,34(4): 252-255.
[7] 余富杰,赵大威,蒋小娟.乳腺癌术后相关淋巴水肿的治疗研究进展
[J].重庆医学,2021,50(23):4115-4119.
[8] 张雨田,屈子怡,谢芝宏,等.乳腺癌相关淋巴水肿的危险因素及治疗进展
[J].血管与腔内血管外科杂志,2021,7(11): 1344-1348,1379.
[9] 李晓露,王惠芬,刘细友,等.综合消肿方法治疗乳腺癌术后放疗后上肢淋巴水肿临床观察
[J].湖北中医大学学报, 2023, 25(3):73-76.
[10] Document C.The diagnosis and treatment of peripheral lymphedema:2020 consensus document of the International Society of Lymphology
[J].Lymphology,2020,53(1):3-19.
[11] Allam O,Park KE,Chandler L,et al.The impact of radiation on lymphedema:a review of the literature
[J].Gland Surg,2020, 9(2): 596.
[12] Kwon JG, Kim Y, Jang MY, et al. The quality of life after lympha ticovenous anastomosis in 118 lower limb lymphedema patients.Arch Plast Surg, 2023, 50(5): 514-522.
[13] Yang JC, Wu SC, Hayashi A, et al. Selection of optimal functional lymphatic vessel cutoff size in supermicrosurgical lymphaticovenous anastomosis in lower extremity lymphedema. Plast Reconstr Surg, 2022, 149(1): 237-246.
[14] Gabriele G, Nigri A, Chisci G, et al. Combination of suprami crosurgical lymphatico-venular anastomosis (sLVA) and lymphsparing liposuction in treating cancer-related lymphedema:Rationale for a regional one-stage approach. J Clin Med, 2024,13(10): 2872.
[15] Wallmichrath J, Schöpfer D, Frick A, et al. Investigations on the donor limb after harvest of lymphatic vessels for lymphedema surgery.J Vasc Surg Venous Lymphat Disord,2023,11(1):167-176.
[16] Ciudad P, Agko M, Patel KM, et al. A single-stage triple-inset vascularized gastroepiploic lymph node transfers for the surgical treatment of extremity lymphedema. Microsurgery, 2021, 41(1):97-99.
[17] Wu S, Coombs DM, Gurunian R. Liposuction: Concepts, safety,and techniques in body-contouring surgery. Cleve Clin J Med,2020, 87(6): 367-375.
[18] Donahue PMC, MacKenzie A, Filipovic A, et al. Advances in the prevention and treatment of breast cancer-related lymphedema.Breast Cancer Res Treat, 2023, 200(1): 1-14.
[19] 刘高明,刘媛媛,胡进,等.综合消肿疗法在妇科恶性肿瘤术后外阴淋巴水肿中的应用
[J].解放军护理杂志,2021,38 (10): 73‐76.
[20] ANBARI A B,WANCHAI A,ARMER J M.Breast cancer‐related lymphedema and quality of life: a qualitative analysis over years of survivorship
[J].Chronic Illness,2021,17(3): 257‐268.
[21] ZHENG Y, ZHANG S, LI J, et al.“Overlapping lockup” lymphaticovenous anastomosis: A useful addition for supermicrosurgeons
[J]. J Vasc Surg Venous Lymphat Disord, 2024, 12(1):101684.
[22] CHUNG J H, BAEK S O, PARK H J, et al. Efficacy and patient satisfaction regarding lymphovenous bypass with sleeve-in anastomosis for extremity lymphedema
[J]. Arch Plast Surg,2019,46(1):46-56.
[23] FORTE A J, KHAN N, HUAYLLANI M T, et al. Lymphaticovenous anastomosis for lower extremity lymphedema: A systematic review
[J]. Indian J Plast Surg,2020,53(1):17-24.

引用本文

冯亮,夏华,吴卫红,饶弋,朱思,谭岁赛*. 淋巴水肿的发病机制及治疗进展研究 [J]. 国际临床研究杂志. 2025; 9; (6). 38 - 43.

文献评论

相关学者

相关机构